Thymosin Alpha-1

Overview

Thymosin Alpha-1 (Ta1, thymalfasin) is a synthetic peptide identical to a 28-amino-acid fragment of prothymosin made by the thymus, the gland where T cells mature. It works as an immune modulator: it helps dendritic cells present antigens, promotes the maturation of T cells, biases responses toward an antiviral profile and raises natural-killer-cell activity, while also helping keep inflammation and tolerance in balance. Crucially, it tends to normalize immune function rather than force it in one direction. Under the brand name Zadaxin it has been used clinically for decades in parts of Asia, Europe and South America.

It is a distinct molecule from thymalin (a different, multi-peptide thymic-extract preparation) and from thymosin beta-4 / TB-500 (a tissue-repair peptide); those are covered on their own pages and should not be conflated with Ta1.

Evidence Quality

The evidence is genuinely mixed, which is why this sits around a B-minus. On one hand, Ta1 is an actual approved medicine in roughly 30 countries with a supportive body of randomized trials in chronic hepatitis B. On the other, its broader immune-boosting reputation rests on studies of variable quality. Sepsis is the clearest cautionary example: a small single-blind trial (ETASS, 2013) suggested a mortality benefit and pooled meta-analyses looked favorable, but the largest, properly double-blinded phase 3 trial (TESTS, 2025, about 1,100 patients) found no reduction in 28-day mortality.

What the Research Shows

Hepatitis B and C is the strongest human evidence and the basis for approval, with phase III trials and meta-analyses reporting improved sustained virological response versus placebo, used alone or with interferon. In cancer support, randomized data back its use as an adjuvant to reduce chemotherapy-related immune suppression. In sepsis and critical illness the signals are inconsistent: a 2025 meta-analysis showed an overall mortality benefit that disappeared in the high-quality subgroups, and the definitive TESTS trial was negative. COVID-19 and general immune-support data are mostly observational and hypothesis-generating.

Dosage Notes

The established clinical dose is 1.6 mg by subcutaneous injection, twice weekly, spaced several days apart. Approved hepatitis courses run 6 to 12 months. Hospital sepsis studies used a far more intensive schedule (1.6 mg twice daily for several days), which is an inpatient research protocol, not something for self-administration. Community protocols generally stay at or near the 1.6 mg twice-weekly dose in blocks of about 4 to 12 weeks.

Who Should Be Cautious

Because it acts on the immune system, people with autoimmune conditions, organ-transplant recipients and others on immunosuppressive therapy should be cautious, since modulating immunity could theoretically worsen their situation or interact with treatment. Safety has not been established in pregnancy or breastfeeding. Anyone using it for a serious condition such as hepatitis should do so under medical supervision with appropriate monitoring, not as a replacement for standard care.

Availability

Thymosin Alpha-1 is approved and prescribed as a medicine (Zadaxin / thymalfasin) in roughly 30 countries, but it is not FDA-approved in the United States, where it carries only orphan-drug designations for specific conditions. As a result, versions sold by US research-peptide suppliers are labeled for research use only, and their purity, sterility and dosing accuracy are not guaranteed by any regulator.

Bottom Line

Ta1 is one of the better-validated immune peptides: a real approved drug with a plausible mechanism and decades of use in hepatitis and cancer support. But its evidence is strongest exactly where it is approved and weaker for the general immune-resilience uses many people buy it for, especially after a large negative sepsis trial. Treat it as a medicine with real but bounded evidence, keep expectations modest, and be careful if you have any autoimmune or immunosuppression concerns.